BTR Capital Management Inc. reduced its holdings in shares of CVS Health Corp (NYSE:CVS) by 9.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 133,757 shares of the pharmacy operator’s stock after selling 14,683 shares during the quarter. CVS Health makes up about 1.9% of BTR Capital Management Inc.’s portfolio, making the stock its 19th biggest holding. BTR Capital Management Inc.’s holdings in CVS Health were worth $9,697,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of CVS. Wealthcare Advisory Partners LLC boosted its stake in CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after purchasing an additional 991 shares during the period. Fieldpoint Private Securities LLC boosted its stake in CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after purchasing an additional 1,000 shares during the period. Arcadia Investment Management Corp MI boosted its stake in CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after purchasing an additional 726 shares during the period. MPS Loria Financial Planners LLC bought a new stake in CVS Health in the 2nd quarter valued at $119,000. Finally, Cerebellum GP LLC bought a new stake in CVS Health in the 4th quarter valued at $130,000. Institutional investors own 84.12% of the company’s stock.
CVS Health Corp (NYSE:CVS) opened at $69.01 on Tuesday. The firm has a market capitalization of $70,010.00, a price-to-earnings ratio of 10.67, a price-to-earnings-growth ratio of 1.15 and a beta of 1.03. The company has a quick ratio of 0.52, a current ratio of 1.02 and a debt-to-equity ratio of 0.59. CVS Health Corp has a fifty-two week low of $66.45 and a fifty-two week high of $84.00.
In other news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Helena Foulkes sold 19,965 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $71.04, for a total value of $1,418,313.60. Following the transaction, the executive vice president now directly owns 65,072 shares of the company’s stock, valued at approximately $4,622,714.88. The disclosure for this sale can be found here. 0.61% of the stock is owned by insiders.
Several analysts recently issued reports on the company. Needham & Company LLC upgraded CVS Health from a “buy” rating to a “strong-buy” rating and boosted their price target for the company from $88.00 to $100.00 in a research note on Tuesday, January 30th. Mizuho set a $95.00 price target on CVS Health and gave the company a “buy” rating in a research note on Wednesday, January 24th. Cowen restated an “outperform” rating and issued a $99.00 price target (up from $81.00) on shares of CVS Health in a research note on Thursday, January 18th. Vetr downgraded CVS Health from a “hold” rating to a “sell” rating and set a $76.66 price target for the company. in a research note on Tuesday, January 16th. Finally, ValuEngine downgraded CVS Health from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $87.03.
WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/13/cvs-health-corp-cvs-shares-sold-by-btr-capital-management-inc.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.